Stroke & Hyperbarics

Hyperbaric Oxygen Therapy sessions last 60 minutes. Schedule Hyperbaric Oxygen Therapy daily for the number of sessions recommended by your physician and/or based on the purchased package. Consider a baseline Hyperbaric Brain Map or QEEG before starting Hyperbaric Oxygen Therapy to evaluate concerns and observe benefit overtime.

Each year nearly 800,000 strokes occur, averaging one every 40 seconds, making it the fifth leading cause of death in the U.S. A stroke occurs when blood flow to any part of the brain is cut off due to an aneurysm, leaking blood vessels, or a blood clot. Cut off from the blood supply, and thus oxygen, the brain cells in this region will die. The loss of brain cells can affect any aspect of day to day functioning, including memory and muscle control of the face or limbs.

Due to the hypoxic nature of strokes, it has been postulated that by increasing levels of oxygen, the effects of the stroke may be improved. Many different studies support this theory and believe that hyperbaric oxygen therapy (HBOT) can help an individual to improve cognition as well as physical abilities such as gait. Furthermore, they have found that the sooner HBOT is administered after the occurrence of stroke, the more recovery can be expected. Many believe that the optimal time frame would be no greater than six hours after the stroke. However, some studies show that recovery is still possible days months or even years post-stroke.

Hyperbaric oxygen therapy can also be used in the prevention of strokes. Strokes are characterized by a lack of adequate blood supply to the brain and HBOT has been shown to increase blood flow to the brain as well as promote angiogenesis (the creation of new blood vessels). Further studies have demonstrated the benefits of HBOT for strokes including the following:

Stroke Recovery
  • Faster Overall Recovery
  • Improves Vision and Speech
  • Reduces Paralysis
  • Accelerates Gross/Fine Motor Skills
  • Increases Penumbra Tissue Recovery
  • Stimulates Blood Vessel Growth
  • Escalates Brain Tissue Repair
  • Alleviates Spasticity
Stroke Prevention
  • Stimulates Blood Vessel Growth Improving Blood Flow
  • Reduces Atherosclerosis
  • Decreases Oxidative Stress in the Brain
  • Preconditions the Brain to Enable Neuroprotective Properties

REFERENCE

  1. Efrati, S., Fishlev, G., Bechor, Y., Volkov, O., Bergan, J., Kliakhandler, K., … Golan, H. (2013). Hyperbaric oxygen induces late neuroplasticity in post stroke patients–randomized, prospective trial. PloS one, 8(1), e53716. doi:10.1371/ journal.pone.0053716
  2. Liska, G. M., Lippert, T., Russo, E., Nieves, N., & Borlongan, C. V. (2018). A Dual Role for Hyperbaric Oxygen in Stroke Neuroprotection: Preconditioning of the Brain and Stem Cells. Conditioning medicine, 1(4), 151–166.
  3. International Hyperbaric Association. (2014). Stroke. Retrieved from https:// ihausa.org/Stroke.html

Study: Neurological Function Improved in Post-Stroke Patients with HBOT

In 2013 a prospective, randomized, controlled trial focused on the introduction of 6 to 36 months prior to inclusion and had at least one motor dysfunction, were randomly assigned to treated and cross-over groups. The treated group received two months of 40, one hour HBOT sessions, five days a week. Whereas the crossover group was evaluated after one month with no HBOT and again after one month following HBOT, utilizing the same treatment protocol. The evaluating physicians found that neurological function, brain activity and quality of life of all treated patients improved after HBOT. Brain scan results directly correlated with clinical improvements and indicated that HBOT can lead to significant neurological improvements in post-stroke patients, even at chronic late stages. The observed clinical improvements indicated that new brain connections can be activated long after a stroke occurs.

REFERENCE

  1. Efrati S, Fishlev G, Bechor Y, Volkov O, Bergen J, et al. (2013) Hyperbaric Oxygen Induces Late Neuroplasticity in Post Stroke Patients – Randomized, Prospective Trial. PloS ONE 8(1): e53716

These statements have not been evaluated or approved by the FDA. All of the statements made on this document are not anecdotal and have been taken directly from clinical data.